Global Market Research Reports : Ken Research: Europe Cancer Diagnostic Market Forecasts

Tuesday, October 15, 2019

Increase in Prevalence of Cancer Expected to Drive Europe Cancer Screening Market over the Forecast Period: Ken Research

Certain tests help find precise types of cancer before signs or symptoms appear, called cancer screening. It main goal is to reduce the number of people who develop the disease and reduce the number of people who die from disease & prevent deaths from cancer altogether. It involves urine tests, blood tests and medical imaging tests.

Some of the risk associated with cancer screening are increased testing, false positives test results, over diagnosis & over treatment and false reassurance.

According to study, “Europe Cancer Screening Market (2018-2023)” the key companies operating in the Europe cancer screening market are F. Hoffman-La- Roche Ltd, Johnson & Johnson, Bayer AG, Pfizer Inc., Merck & co., Abbott Laboratories Inc., Becton, Dickinson and Company, Agilent Technologies, GE Healthcare, C. R. Bard, Inc., Koninklijhe Philips N.V., Hologic Inc., Siemens Healthcare GmbH, Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen. Healthcare professionals are focusing on expansion of effective screening solutions to check prevalence level. Early detection rises the success rate of treatment regimens. As a result, healthcare agencies & market players are promoting routine checkups through various awareness programs.

Based on screening procedure, cancer screening market is segmented into laboratory, imaging, biopsy, genetic, and endoscopy tests. All screening procedures includes some tests such as breast self-examination test, clinical breast examination test, Magnetic resonance imaging (MRI), mammography and others. Mammography is a most common & popular screening test employed for breast tumor screening. Based on genders, market is segmented into men and women. Based on application, market is segmented into lung, melanoma, kidney, breast, and colorectal cancer. Kidney segment is projected to witness lucrative growth owing to rise in consumption of tobacco & alcohol during the forecast period. In addition, based on end-use, market is segmented into laboratories, hospitals, and independent physicians & clinics.

The cancer screening market is driven by increase in prevalence of cancer, followed by rise in adoption of a sedentary lifestyle, increase in aging population, growth in focus of key players in the emerging economies, rise in government investments for research & development (R&D), improvement in healthcare infrastructure, and healthcare, huge patient population, growth in technological advancements & product innovations and change in environmental conditions. However, lack of associated funding & transparency in medical procedures and stringent regulations along with regulatory inter & intra state barriers may impact the market. Moreover, rise in artificial intelligence and forthcoming health revolution are key opportunities for market.

Based on geography, cancer screening market is categorized as France, United Kingdom (UK) and Germany. It is estimates that the market will be reached at rapid pace owing to increase in awareness about cancer and rise in government initiatives for funding in the region. Various organizations are undertaking many initiatives to spread awareness regarding benefits of early detection, breast cancer, and available treatment options. It is expected that future of the market will be bright due to rise in availability of funds for research over the forecast period. The market is anticipated to grow at a CAGR of approximately 8.1% resulting in an annual revenue of US $22.43 billion during the forecast period (2018-2023).

For more information, click on the link below:

Europe Cancer Screening Market

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

+91 9015378249

Friday, September 27, 2019

Increasing Landscape of the Europe Cancer Screening Market Outlook: Ken Research

Buy Now

Worldwide, the cancer the most embryonic syndrome in the present era. There are some types of the cancer persevering in a human body such as cervical, breast, liver, blood, kidney, pancreatic, ovarian, colorectal, lung cancers and several others. The cure at an early stage can treat the syndrome and restrict the syndrome severity. In the addition, the research institutes have the huge implementation rate of cancer cure devise owing to the heavy funding from the regulatory authorities and private institutions.

The effective augment in the incidence of the cancer syndrome, increasing awareness related to the healthcare and the present technological development in the diagnostic devices are few of the aspects fueling the market growth more actively throughout the short span of time. On the other hand, the great price of the diagnostic devices, stringent regulations for the fresh product approvals are the aspects restricting the market growth.

According to the report analysis, ‘Europe Cancer Screening Market (2018-2023)’ states that in the Europe cancer screening market, there are numerous key players which recently functioning more effectively for leading the fastest market growth and dominating the high value of market share throughout the forecasted period while delivering the better consumer satisfaction, increasing the applications of the technologies, decreasing the price of the services and devices and studying the strict regulations of the regulatory authorities includes F. Hoffman La Roche Ltd, Bayer AG, Johnson & Johnson, Pfizer, Merck & Co., and several others.

Not only has this, the giants in the market of cancer screening are implementing the strategies to enlarge the market share, increasing the value of profit and generating the high amount of revenue which further proved to be profitable for leading the fastest market growth. Additionally, the Europe after North America is the second foremost market leading the cancer screening market. The market is calculated to increase at a compound annual growth rate of (CAGR) of 8.1% resulting in an annual revenue of USD 22.43 Bn during the projection period of 2018-2023. The significant increase in the aging populace along with the growth in the number of cancer incidences is a key fueling aspect for the market. The Western Europe is shifting fast towards the implementation of the performance-based remuneration systems.

Although, on the basis of end users, the market is sectored into hospitals, laboratories and independent physicians and clinics. However, the Laboratory sector will monitor a progressive growth during the review period of 2018-2023 while the hospital sector will account for the thoroughgoing revenue of USD 11.18 billion during the review period.

In addition on the basis of screening type, the market is divided into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic, biopsy and endoscopy will be the important sector during the forecast period of 2018-2023. For instance, by application type, the market can be categorized into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will attain a larger share of the market during the review period of 2018-2023. By countries, the market is classified into the United Kingdom (U.K.), France and Germany.

Not only has this, the effective augment in the aging populace, changing environmental conditions along with the acceptance of a sedentary lifestyle is underwriting to the more cancer-related cases. Therefore, it is predicted that the market of cancer screening in Europe will increase more positively over the coming years.